

=> s 11 and tumor/ab

1332 TUMOR/AB

L2 42 L1 AND TUMOR/AB

=> d 1-10

1. 5,310,653, May 10, 1994, Tumor marker protein and antibodies thereto for cancer risk assessment or diagnosis; Margaret Hanausek-Walaszek, et al., 435/7.23; 424/88; 435/7.92; 530/358, 387.7, 388.8, 389.7 [IMAGE AVAILABLE]

2. 5,308,614, May 3, 1994, Methods for the production of antibodies and induction of immune responses to tumor-associated gangliosides by immunization with ganglioside lactones; Sen-Itiroh Hakomori, 424/88, 93U; 436/519, 524; 514/23, 42, 54 [IMAGE AVAILABLE]

3. 5,290,551, Mar. 1, 1994, Treatment of melanoma with a vaccine comprising irradiated autologous melanoma tumor cells conjugated to a hapten; David Berd, 424/88, 85.2 [IMAGE AVAILABLE]

4. 5,284,827, Feb. 8, 1994, Systemic treatment of metastatic cancer with platelet factor 4; Theodore Maione, et al., 514/12; 424/88; 435/69.6; 514/2; 530/324, 380 [IMAGE AVAILABLE]

5. 5,270,038, Dec. 14, 1993, Tumor necrosis factor receptors on microorganisms; Gary R. Klimpel, et al., 424/88, 85.1, 92; 435/252.1, 252.8, 255.4, 849, 879, 922 [IMAGE AVAILABLE]

6. 5,250,297, Oct. 5, 1993, Tumor-associated antigen, antibodies, compositions and uses therefor; Lana S. Grauer, et al., 424/88; 530/350, 388.8, 395, 403 [IMAGE AVAILABLE]

7. 5,242,823, Sep. 7, 1993, Cloning of the 38kd Mycoplasma hyorhinis regression-associated antigen; George C. Fareed, et al., 435/252.3; 424/88; 435/69.1, 69.3, 252.33, 320.1; 530/350, 403, 806, 825; 536/23.7 [IMAGE AVAILABLE]

8. 5,208,022, May 4, 1993, Non-malignant cells coupled to adjuvants and their use in a method to induce anti-tumor immunity; Arnold E. Eggers, 424/88, 89, 90, 91, 92, 93U; 435/240.1; 512/2; 530/402, 403, 404, 405, 406 [IMAGE AVAILABLE]

9. 5,192,537, Mar. 9, 1993, Method of treating renal cell carcinoma using activated mononuclear cells, renal tumor antigen and cimetidine; Michael E. Osband, 424/85.2, 88, 93R, 534; 514/2, 339, 482 [IMAGE AVAILABLE]

10. 5,118,500, Jun. 2, 1992, Pharmaceutical containing TNF inhibitor; Heinz Hanel, et al., 424/85.1, 88; 514/21 [IMAGE AVAILABLE]

=> d ab 1-8

US PAT NO: 5,310,653 [IMAGE AVAILABLE]

L2: 1 of 42

ABSTRACT:

A tumor -associated marker protein was purified and antibodies thereto developed for cancer diagnosis and assessment of cancer risk associated with the long-term use of synthetic steroid hormones, both contraceptive and non-contraceptive, and other drugs that exhibit tumor promotional

properties. The marker protein and antibodies thereto provided are interspecies immunologically cross-reactive.

In summary, the marker p65 tumor -associated factor of the present invention has the following characteristics:

- (a) binds substantially completely to a phenyl hydrophobic interaction column in a buffer containing 20% ammonium sulfate and eluted at ca. 16% ammonium sulfate;
- (b) localized primarily in the nuclear envelopes with only small amounts present in the cytoplasm from where is released to the blood circulation in vivo or cell culture medium in vitro;
- (c) induced in normal, adult tissues by chemical carcinogens (initiators) but not by tumor promoters, the carcinogen-induced production being enhanced by the latter.

Also disclosed herein are processes for purifying the 65 kDa tumor marker from plasma, tumor cytosol or ascitic fluid of carcinoma bearing animals; processes for producing antisera and purified antibody preparations to the 65 kDa tumor marker; and methods using antibody to the 65 kDa to diagnose or assess the likelihood of cancer.

US PAT NO: 5,308,614 [IMAGE AVAILABLE]

L2: 2 of 42

ABSTRACT:

The present invention relates to an improved method for the production of antibodies to tumor -associated gangliosides using ganglioside lactones. The resulting antibodies are useful in the detection and treatment of tumors containing gangliosides. The present invention also relates to methods of treatment of tumors by active immunization using ganglioside lactones.

US PAT NO: 5,290,551 [IMAGE AVAILABLE]

L2: 3 of 42

ABSTRACT:

The invention is a haptenized tumor vaccine for the treatment of cancer. Treatment of cancer patients with an autologous, vaccine preceded by low dose cyclophosphamide (CY) induces delayed-type hypersensitivity (DTH) to melanoma cells, and in some cases, regression of metastatic tumors. The efficiency of the process has been increased by immunizing with tumor cells conjugated to the hapten such as DNP, TNP or AED. Additional embodiments of the vaccine include: 1) combining the vaccine with immunomodulating drugs, such as, interleukin-2 (IL2); and 2) purifying the active components of the vaccine by extracting antigens from cancer cells to produce a chemically-defined, haptenated vaccine. The treatment may also be extended to include other types of human cancer.

US PAT NO: 5,284,827 [IMAGE AVAILABLE]

L2: 4 of 42

ABSTRACT:

The subject invention concerns a novel treatment for cancer. Specifically, the invention concerns the systemic administration of recombinant Platelet Factor Four (rPF4) to inhibit tumor growth in a mammal having metastatic cancer.

US PAT NO: 5,270,038 [IMAGE AVAILABLE]

L2: 5 of 42

ABSTRACT:

Cytokine receptors for tumor necrosis factor .alpha. which are found on microorganisms may, if bound with exogenous TNF.alpha., enhance the response of natural killer cells activated by the microorganisms, or increase TNF.alpha. production by peripheral blood lymphocytes treated

with the microorganisms. Microorganisms with receptor-bound exogenous TNF. α . have enhanced cellular invasion ability which may change the immune response thereto. Clinical and pharmaceutical applications of these discoveries including vaccines with increased efficacy are provided.

US PAT NO: 5,250,297 [IMAGE AVAILABLE]

L2: 6 of 42

ABSTRACT:

A novel tumor -associated antigen expressed by lung adenocarcinoma is disclosed. The antigen, characterized by monoclonal antibody LA20207, has a molecular weight in the range of about 50,000 to about 80,000 daltons and an isoelectric point in the range of about 4.9 to about 6.5. Antibodies directed against the antigen, methods for their production and diagnostic and therapeutic uses therefor are also provided.

US PAT NO: 5,242,823 [IMAGE AVAILABLE]

L2: 7 of 42

ABSTRACT:

Regression associated antigens (RAAs) are identified in material from neoplastic cells by their immunological reactivity with regression associated antibodies from the serum of patients diagnosed as undergoing regression of a tumor . Regression associated antibodies (RAAbs) are identified by their absence during progression of a neoplastic disease state and by their presence in a diagnosed state of regression. RAAs have been purified and used to monitor the condition of cancer patients. Production of RAAbs and treatments employing those antibodies are described. It is herein disclosed that RAAs are expressed by *M. hyorhinis* and are also expressed by expression of provided nucleotide sequences in recombinant host cells, particularly nucleotide sequence for 38 kd and 43 kd RAAs as expressed in *E. coli*. RAAs and nucleic acids encoding RAAs (or portions thereof) and RAAbs may be used in diagnostic assays and immunotherapy. RAAbs and fragments portion thereof may be used in passive immunization therapy and radioisotope or magnetic resonance scanning.

US PAT NO: 5,208,022 [IMAGE AVAILABLE]

L2: 8 of 42

ABSTRACT:

A vaccine composition for inducing anti- tumor immunity comprising non-malignant cells, preferably syngeneic non-malignant cells, coupled with adjuvant compounds. The nonmalignant immunizing cells of the present invention induce T-cell mediated cytotoxicity which cross-reacts with tumor cells, providing in vivo protection against the tumor cells. Examples of tumors which may be treated by administration of the vaccine compositions include fibrosarcomas, glioblastomas, and all solid and lymphoid tumors.

=> LOG Y

U.S. Patent & Trademark Office LOGOFF AT 15:59:23 ON 13 JUN 94

+++
OK
ATH
OK
C